Table 1 Characteristics of the included studies
References | Year | Country | No. of patients | Gender (M/F, n) | Age range (years) | Method | Antibody dilution | Counting method | Cut-off staining | Reduced Beclin-1 expression (%) | OS data provided |
|---|---|---|---|---|---|---|---|---|---|---|---|
Ding [15] | 2008 | China | 300 | 252/48 | NR | IHC | 1:50 | IRS* | 10% | 205/300 (68.33) | Yes |
Kang [21] | 2013 | China | 50 | 47/3 | 28–71 | IHC | NR | IRS | 4 | 11/50 (22.00) | No |
Lee [22] | 2013 | Korea | 190 | 158/32 | 29–76 | IHC | NR | IRS | 6 | 179/190 (94.21) | Yes |
Guo [26] | 2013 | China | 54 | 39/15 | 33–75 | IHC | 1:150 | IRS | 3 | 10/54 (18.52) | No |
Qiu [14] | 2014 | China | 103 | 85/18 | 21–79 | IHC | 1:100 | IRS | 8 | 81/103 (78.64) | Yes |
Wu [16] | 2014 | China | 156 | 143/13 | NR | IHC | 1:100 | IRS | 6 | 83/156 (53.21) | Yes |
Osman [23] | 2015 | Egypt | 65 | 51/14 | 40–74 | IHC | 1:100 | IRS* | 10% | 32/65 (49.23) | No |
Yang [27] | 2015 | China | 50 | 39/11 | 26–74 | IHC | NR | IRS | 3 | 11/50 (22.00) | No |
Al-Shenawy [24] | 2016 | Egypt | 35 | 20/15 | 23–75 | IHC | 1:350 | IRS | 1 | 18/35 (51.43) | No |
Zhou [25] | 2016 | China | 83 | 69/14 | NR | IHC | 1:100 | NR | NR | 45/83 (54.22) | Yes |